These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36351631)

  • 1. Successful management of pelvic recurrence of MSI-High endometrial cancer by total pelvic exenteration followed by administration of pembrolizumab:A case report.
    Kojima M; Soeda S; Okabe C; Sato T; Kamo N; Ueda M; Endo Y; Nomura S; Tokuda E; Furukawa S; Kataoka M; Fujita S; Saji S; Watanabe T; Fujimori K
    Fukushima J Med Sci; 2022 Dec; 68(3):191-195. PubMed ID: 36351631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laparoscopic Anterior Pelvic Exenteration with Super Radical Parametrectomy for a Recurrent Low-Grade Endometrial Sarcoma That is Resistant to Hormone Therapy and Chemotherapy.
    Kanao H; Hisa T; Omi M; Nagashima M; Okamoto S; Aoki Y; Tanigawa T; Matoda M; Okamoto S; Nomura H; Omatsu K; Kato K; Utsugi K; Takeshima N
    J Minim Invasive Gynecol; 2019 Jan; 26(1):34-35. PubMed ID: 29621612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pelvic exenteration for recurrent endometrial cancer.
    Barakat RR; Goldman NA; Patel DA; Venkatraman ES; Curtin JP
    Gynecol Oncol; 1999 Oct; 75(1):99-102. PubMed ID: 10502433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pelvic Exenterations for Advanced and Recurrent Endometrial Cancer: Clinical Outcomes of 40 Patients.
    Schmidt AM; Imesch P; Fink D; Egger H
    Int J Gynecol Cancer; 2016 May; 26(4):716-21. PubMed ID: 26937752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful salvage treatment of recurrent endometrial cancer with bulky central tumor and extensive lymph node metastasis. A case report.
    Wu YC; Huang SL; Chuang CK; Jung SM; Lai CH
    Eur J Gynaecol Oncol; 2004; 25(6):739-41. PubMed ID: 15597856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
    Barrington DA; Dilley SE; Smith HJ; Straughn JM
    Gynecol Oncol; 2019 May; 153(2):381-384. PubMed ID: 30808517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total pelvic exenteration for primary and recurrent malignancies.
    Ferenschild FT; Vermaas M; Verhoef C; Ansink AC; Kirkels WJ; Eggermont AM; de Wilt JH
    World J Surg; 2009 Jul; 33(7):1502-8. PubMed ID: 19421811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total Pelvic Exenteration for Recurrent Endometrial Sarcoma - A Case Report.
    Suciu N; Bălescu I; Bacalbaşa N
    Chirurgia (Bucur); 2015; 110(5):486-9. PubMed ID: 26531797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical management of advanced or recurrent endometrial cancer.
    Chi DS; Barakat RR
    Surg Clin North Am; 2001 Aug; 81(4):885-96. PubMed ID: 11551132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Entirely robotic total pelvic exenteration.
    Vasilescu C; Tudor S; Popa M; Aldea B; Gluck G
    Surg Laparosc Endosc Percutan Tech; 2011 Aug; 21(4):e200-2. PubMed ID: 21857461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pelvic exenteration for recurrent rectal cancer.
    Avradopoulos KA; Vezeridis MP; Wanebo HJ
    Adv Surg; 1996; 29():215-33. PubMed ID: 8720005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total Pelvic Exenteration for Recurrent Endometrial Sarcoma - A Case Report.
    Suciu N; Bălescu I; Bacalbaşa N
    Chirurgia (Bucur); 2015; 110(4):396-400. PubMed ID: 26305208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathologic tumor spreading in primary ovarian cancer with modified posterior exenteration.
    Kato K; Nishikimi K; Tate S; Kiyokawa T; Shozu M
    World J Surg Oncol; 2015 Jul; 13():230. PubMed ID: 26228239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pelvic exenteration for recurrent endometrial adenocarcinoma: a retrospective multi-institutional study about 21 patients.
    Chiantera V; Rossi M; De Iaco P; Koehler C; Marnitz S; Gallotta V; Margariti AP; Parazzini F; Scambia G; Schneider A; Vercellino GF
    Int J Gynecol Cancer; 2014 Jun; 24(5):880-4. PubMed ID: 24685828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laparoscopic assessment improves case selection for exenterative surgery in recurrent cervical and endometrial cancer.
    Heath OM; Bryan SJ; Sohaib A; Barton DPJ
    J Obstet Gynaecol; 2021 Nov; 41(8):1252-1256. PubMed ID: 33646894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Curative pelvic exenteration for recurrent cervical carcinoma in the era of concurrent chemotherapy and radiation therapy. A systematic review].
    Sardain H; Lavoué V; Foucher F; Levêque J
    J Gynecol Obstet Biol Reprod (Paris); 2016 Apr; 45(4):315-29. PubMed ID: 26874666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration.
    Morris M; Alvarez RD; Kinney WK; Wilson TO
    Gynecol Oncol; 1996 Feb; 60(2):288-91. PubMed ID: 8631553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
    Marth C; Tarnawski R; Tyulyandina A; Pignata S; Gilbert L; Kaen D; Rubio MJ; Frentzas S; Beiner M; Magallanes-Maciel M; Farrelly L; Choi CH; Berger R; Lee C; Vulsteke C; Hasegawa K; Braicu EI; Wu X; McKenzie J; Lee JJ; Makker V
    Int J Gynecol Cancer; 2022 Jan; 32(1):93-100. PubMed ID: 34799418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies.
    Andikyan V; Khoury-Collado F; Sandadi S; Tew WP; O'Cearbhaill RE; Konner JA; Sonoda Y; Barakat RR; Chi DS; Abu-Rustum NR
    Int J Gynecol Cancer; 2013 Jun; 23(5):923-8. PubMed ID: 23698798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of recurrent endometrial cancer with long-term complete remission following pembrolizumab-induced severe immune-related adverse event colitis.
    Yamamoto A; Nagashima T; Imai Y; Akitsu K; Yamanaka Z; Nishi H
    J Obstet Gynaecol Res; 2022 Oct; 48(10):2630-2634. PubMed ID: 35801666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.